CellCept (Mycophenolate Mofetil Capsules) and Theophylline and guaifenesin

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.

In vitro studies have shown that mycophenolic acid in concentrations up to 100 mcg/mL decreases protein binding of theophylline from 53% to 45%. The clinical significance of this interaction is unknown. Decreased protein binding theoretically could lead to increased plasma theophylline concentrations. However, clinical toxicity has not been reported. It may be appropriate to monitor more closely patients receiving theophylline or other methylxanthine derivatives with mycophenolic acid products. Patients should be advised to contact their physician if they experience potential symptoms of theophylline toxicity such as nausea, vomiting, diarrhea, headache, restlessness, insomnia, and irregular heartbeat.

CellCept (Mycophenolate Mofetil Capsules)

Generic Name: mycophenolate mofetil

Brand name: Cellcept, Myfortic, MMF

Synonyms: CellCept

What is CellCept (Mycophenolate Mofetil Capsules)?

Theophylline and guaifenesin

Generic Name: guaifenesin / theophylline

Brand name:

Synonyms: Theophylline and guaifenesin (Oral)

What is Theophylline and guaifenesin?